About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

A Study to Assess the Use of Methylone in the Treatment of PTSD

NCT05741710·16 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Transcend Therapeutics

Age

18–65

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Meets the DSM-5 criteria for current moderate to severe PTSD diagnosis, with a symptom duration of at least 6 months
CAPS-5 score of ≥35 at Screening.
Failed at least one treatment for PTSD (either psychotherapy or pharmacological treatment).
Proficient in reading and writing in local language sufficient to complete questionnaires.
Free from any other clinically significant illness or disease

You may not be if

Primary diagnosis of any other DSM-5 disorder
Body mass index (BMI) \<18 kg/m2 or ≥40 kg/m2.
Smokes an average of \>10 cigarettes and/or e-cigarettes per day
Uncontrolled hypertension at Screening
Use of a psychedelic (e.g., LSD, psilocybin, DMT, mescaline), or entactogens such as MDMA, within 12 months of Screening.
Use of an SSRI or other antidepressant within 8 weeks of screening.
Current or previous history of clinically significant cardiovascular/cerebrovascular conditions.

The record

StatusCompleted

PhasePhase 1–2

Taking part79

StartedMar 2023

UpdatedApr 15, 2026

Conditions

Post Traumatic Stress Disorder

Where16

Mountain View Clinical Research
Denver, Colorado, United States
Clinical Neuroscience Solutions - Jacksonville
Jacksonville, Florida, United States
Accel Research Sites
Maitland, Florida, United States

Clareo Health | A Study to Assess the Use of Methylone in the Treatment of PTSD